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The dichotomy of the TGF-β pathway in inflammation, tumor suppression or 
metastases remains elusive. We analyzed TGF-β pathway across all 33 TCGA (The 
Cancer Genome Atlas) tumor types and 9125 samples to address this question. Our 
studies provide new insight into how this pathway is regulated across multiple cancer 
types in TCGA. We comprehensively catalogued 140 TGF-β pathway-related genes that 
are involved in cancer. We found that 41% of all samples have at least one genomic 
alteration in the TGF-β pathway predominantly as mutations. Genome wide mutation and 
CNV analysis suggests that most of those aberrations are due to mutations rather than 
CNVs. Gastrointestinal cancers have the highest alteration frequencies and are enriched 
for mutational hotspots, whereas renal and brain cancers show fewer aberrations. We 
found hotspots in six genes, including the newly identified hotspots on TGFBR2, AVCR2A 
and BMP5. mRNA transcriptomic analyses revealed three clusters of expression, 
increased, decreased or not altered in multiple cancers, with altered expression 
conferring significantly decreased survival in some cancers. Epigenetic and miRNA 
analyses showed that although both the first two clusters (altered levels of the pathway 
members) play key roles in regulating the pathway, the balance of power between them 
these is highly dependent on tumor type. We also determined correlation between TGF-
β pathway and other oncogenic pathways and observed strong positive correlation with 
DNA damage repair and EMT pathways and a strong negative correlation with cell cycle 
pathway. This multidimensional study provides the genomic landscape of TGF-β 
signaling in both individual disease and PanCancer settings to guide future functional and 
therapeutic studies of this key remarkable cancer pathway. 
 
